FindTrial
Sign In

QT-019C

DRUG3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Tianjin Huanhu Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

ANCA Associated Vasculitis (AAV)Connective Tissue Disease-Associated ThrombocytopeniaIIM- Idiopathic Inflammatory MyopathiesImmune Thrombocytopenia (ITP)Multiple SclerosisMyasthenia GravisNeuromyelitis Optica Spectrum DisordersSLE - Systemic Lupus Erythematosus

Early Phase 1

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Not yet recruitingNCT07392528
Tianjin Huanhu HospitalMultiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders
Start: 2026-03-01End: 2028-12-01Target: 15Updated: 2026-02-11
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
Not yet recruitingNCT07416032
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyImmune Thrombocytopenia (ITP)
Start: 2026-02-20End: 2029-03-01Target: 27Updated: 2026-02-17

Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
RecruitingNCT07315087
Institute of Hematology & Blood Diseases Hospital, ChinaANCA Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, IIM- Idiopathic Inflammatory Myopathies +3
Start: 2026-01-01End: 2029-01-18Target: 12Updated: 2026-01-20